Immune context characterization and heterogeneity in primary tumors and pulmonary metastases from renal cell carcinoma.


Journal

Immunotherapy
ISSN: 1750-7448
Titre abrégé: Immunotherapy
Pays: England
ID NLM: 101485158

Informations de publication

Date de publication:
01 2019
Historique:
entrez: 1 2 2019
pubmed: 1 2 2019
medline: 26 11 2019
Statut: ppublish

Résumé

The knowledge of the immune context of renal cell carcinoma (RCC) is useful to predict benefit from immunotherapy. We retrospectively characterized the immune context of RCC patients underwent primary nephrectomy and pulmonary metastasectomy. Intratumoral infiltrating lymphocytes and peritumoral renal infiltrating lymphocytes, lymphocyte subpopulations (CD4 The immune variables demonstrated intralesional and intratumoral heterogeneity. Intralesional lymphocyte heterogeneity reached 76% of cases in T, 28% in M. The heterogeneity rate for PD-L1 expression was from 44% (T) to 56% (M); it correlated with better survival. The immune context of RCC is highly variable both within a given tumor and among primary and metastases.

Identifiants

pubmed: 30702014
doi: 10.2217/imt-2018-0097
doi:

Substances chimiques

B7-H1 Antigen 0
PDCD1 protein, human 0
Programmed Cell Death 1 Receptor 0

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

21-35

Commentaires et corrections

Type : ErratumIn

Auteurs

Melissa Bersanelli (M)

Department of Medical Oncology, University Hospital of Parma, Parma, 43126, Italy.

Letizia Gnetti (L)

Department of Pathological Anatomy & Histology, University Hospital of Parma, Parma, 43126, Italy.

Elena Varotti (E)

Department of Pathological Anatomy & Histology, University Hospital of Parma, Parma, 43126, Italy.

Luca Ampollini (L)

Department of Thoracic Surgery, University Hospital of Parma, Parma, 43126, Italy.

Paolo Carbognani (P)

Department of Thoracic Surgery, University Hospital of Parma, Parma, 43126, Italy.

Francesco Leonardi (F)

Department of Medical Oncology, University Hospital of Parma, Parma, 43126, Italy.

Michele Rusca (M)

Department of Thoracic Surgery, University Hospital of Parma, Parma, 43126, Italy.

Nicoletta Campanini (N)

Department of Pathological Anatomy & Histology, University Hospital of Parma, Parma, 43126, Italy.

Francesco Ziglioli (F)

Department of Urology, University Hospital of Parma, Parma, 43126, Italy.

Clara I Dadomo (CI)

Department of Pathological Anatomy & Histology, University Hospital of Parma, Parma, 43126, Italy.

Francesco P Pilato (FP)

Department of Pathological Anatomy & Histology, University Hospital of Parma, Parma, 43126, Italy.

Alessio Cortellini (A)

Department of Biotechnological & Applied Clinical Sciences, Medical Oncology, St Salvatore Hospital, University of L'Aquila, L'Aquila, 67100, Italy.

Elena Rapacchi (E)

Department of Medical Oncology, University Hospital of Parma, Parma, 43126, Italy.

Giuseppe Caruso (G)

Department of Medical Oncology, University Hospital of Parma, Parma, 43126, Italy.

Enrico M Silini (EM)

Department of Pathological Anatomy & Histology, University Hospital of Parma, Parma, 43126, Italy.

Umberto Maestroni (U)

Department of Urology, University Hospital of Parma, Parma, 43126, Italy.

Sebastiano Buti (S)

Department of Medical Oncology, University Hospital of Parma, Parma, 43126, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH